Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,238,886 papers from all fields of science
Search
Sign In
Create Free Account
Acetylcholine Receptor Antibody Measurement
Known as:
ACHRAB
, Acetylcholine Receptor Antibody
The determination of the amount of acetylcholine receptor antibody present in a sample.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
CDISC SDTM Laboratory Test Terminology by Code
CDISC SDTM Laboratory Test Terminology by Name
Clinical Data Interchange Standards Consortium Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Removal Characteristics of Immunoadsorption with the Tryptophan‐Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis
A. Ohkubo
,
T. Okado
,
+12 authors
S. Naito
Therapeutic apheresis and dialysis
2019
Corpus ID: 133607456
Autoimmune neurological diseases are often treated by immunoadsorption using a conventional plasma separator and tryptophan…
Expand
2019
2019
Analysis of diabetes-associated autoantibodies in children and adolescents with autoimmune thyroid diseases
M. Rydzewska
,
J. Michalak
,
+6 authors
A. Bossowski
Journal of Pediatric Endocrinology & Metabolism…
2019
Corpus ID: 85459933
Abstract Background Zinc transporter 8 autoantibodies (ZnT8Abs) together with glutamic acid decarboxylase autoantibodies (GADAbs…
Expand
2008
2008
[Diagnostics and treatment of myasthenia gravis in children].
S. Kroczka
,
Małgorzata Steczkowska
,
A. Nowak
,
M. Kaciński
Przeglad lekarski
2008
Corpus ID: 20168737
BACKGROUND Myasthenia gravis (MG) is an autoimmunologic disorder. It is characterized by various clinical symptoms and their…
Expand
2008
2008
Differential Diagnosis of Myasthenic Syndromes Acetylcholine Receptor Autoantibodies
Acetylcholine Receptor Autoantibodies
2008
Corpus ID: 14944691
Myasthenia gravis is an acquired, humoral autoimmune disease. Specific acetylcholine receptor autoantibodies (ACHRAB) lead to a…
Expand
2007
2007
[Clinical and electrophysiological characteristics of myasthenia gravis with thymoma: analysis of 72 patients].
Y. Xing
,
L. Cui
,
Y. Guan
,
Ben-hong Li
,
H. Du
Zhonghua yi xue za zhi
2007
Corpus ID: 35290808
OBJECTIVE To investigate the clinical and electrophysiological characteristics of myasthenia gravis with thymoma (MGT). METHODS…
Expand
2005
2005
[Myasthenia in elderly patients: a series of 23 cases].
F. Durand
,
J. Camdessanche
,
L. Jomir
,
J. Antoine
,
P. Cathébras
La Revue de medecine interne
2005
Corpus ID: 24508398
PURPOSE There is evidence that myasthenia gravis is substantially underdiagnosed in older people, for which diagnosis and…
Expand
2005
2005
The secreting expression of recombinant AChR_(α211) and its removal role for AChRAb in myasthenia gravis patient serum
L. Zh
2005
Corpus ID: 87441912
Objective To express recombinant AChR α211 a nd investigate its removal function to AChRAb existed in myasthenia gravis (MG…
Expand
2004
2004
The Effect of AChRAb Injected to Lateral Ventricle on Rats BAEP and EEG
Sun Sheng-gang
2004
Corpus ID: 76329971
Objective To observe the effects of nicotinic acetylcholine receptor antibody (AChRAb) on rats brainstem auditory evoked…
Expand
2002
2002
Study on the clinical effectiveness of thymectomy for myasthenia gravis
T. Pan
,
Hua Yan
,
+11 authors
B. Gao
2002
Corpus ID: 58746977
ObjectiveTo investigate the theoretical basis and clinical significance of thymectomy in the treatment of myasthenia gravis (MG…
Expand
2002
2002
Immunoreaction Between AChRAb Purified from Myasthenia Gravis Sera and Neuronal Nicotinic AChR on Cultured Neurons
L. Rui
2002
Corpus ID: 98921852
Objective The aim of present study is to reveal the mechanism of CNS involvement with MG on cell level in vitro.Methods The…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE